Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 3/20 | 0.63 |
| ▸ | NOTUM | Q6P988 | 7/20 | 0.45 |
| ▸ | DPP4 | P27487 | 1/20 | 0.45 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | FLT3 | P36888 | 1/20 | 0.43 |
| ▸ | KDM1A | O60341 | 2/20 | 0.43 |
| ▸ | MAOB | P27338 | 1/20 | 0.42 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | RXRA | P19793 | 1/20 | 0.41 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.41 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.41 |
| ▸ | MIF | P14174 | 4/20 | 0.41 |
| ▸ | CD74 | P04233 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28337945 | 0.81 | DPP4 (0.49) | MAOANOTUMDPP4ALKL3MBTL1 | |
| SCHEMBL25920363 | 0.80 | ALK (0.42) | MAOANOTUMALKL3MBTL1KDM1A | |
| SCHEMBL16271175 | 0.78 | MAOA (0.65) | MAOANOTUMDPP4L3MBTL1FLT3 | |
| SCHEMBL16479597 | 0.75 | MIF (0.59) | NOTUMP2RX7MIF | |
| SCHEMBL17795447 | 0.74 | MIF (0.58) | P2RX7MIF | |
| SCHEMBL16991685 | 0.73 | MAOA (0.63) | MAOANOTUMDPP4L3MBTL1FLT3 | |
| SCHEMBL22358471 | 0.73 | NOTUM (0.65) | NOTUML3MBTL1P2RX7KDM4EMAPT | |
| SCHEMBL28206334 | 0.73 | RXRA (0.41) | ALKKDM4ERXRAGRIN1GRIN2B | |
| Hydrochloric Acid SCHEMBL30223640 | 0.73 | GRIN1 (0.56) | NOTUMALKKDM1ARXRAGRIN1 | |
| SCHEMBL13527037 | 0.72 | MIF (0.43) | NOTUMALKP2RX7RXRAGRIN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260035341-A1 | FTO INHIBITORS | RPXDS CO LTD (CN) | 2026-02-05 | — | — | US | disclosed |
| EP-4561975-A1 | FTO INHIBITORS | RPXDS Co., Ltd (CN) | 2025-06-04 | — | — | EP | disclosed |
| CN-119546566-A | FTO inhibitors | 瑞璞鑫(苏州)生物科技有限公司 | 2025-02-28 | — | — | CN | disclosed |
| WO-2024022491-A1 | FTO INHIBITORS | RPXDS CO., LTD (CN) | 2024-02-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260035341-A1 | FTO INHIBITORS | FTO, LDLR, GPR119 | MAOA 391/4885NOTUM 1276/4885DPP4 1363/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.